Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 11Tumor-Agnostic 3Sarcoma 1Head & Neck 1Gynecologic 1

Conditions

Endometrial Neoplasms 22Ovarian Neoplasms 16Fallopian Tube Neoplasms 8Breast Neoplasms 5Recurrence 4Carcinoma, Ovarian Epithelial 3Uterine Neoplasms 2Uterine Cervical Neoplasms 2Prostatic Neoplasms 2Progesterone Resistance 2Pancreatic Neoplasms 2Endometrial Hyperplasia 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma 1Peritoneal Neoplasms 1Ovarian Cysts 1Obesity 1Neoplasms by Site 1Neoplasms 1Low-Grade Serous Ovarian Cancer 1Low Grade Serous Ovarian Carcinoma 1Low Grade Serous Ovarian Cancer 1Leiomyosarcoma 1Hydatidiform Mole 1Hereditary Sensory and Autonomic Neuropathies 1Hereditary Breast and Ovarian Cancer Syndrome 1Head and Neck Neoplasms 1Gestational Trophoblastic Disease 1

Interventions

Paclitaxel 28Carboplatin 28pembrolizumab 25Bevacizumab 14liposomal doxorubicin 12Cisplatin 11Gemcitabine 10Radiotherapy 8Drug Therapy 8Cyclophosphamide 8Blood Specimen Collection 8Topotecan 7Nivolumab 7olaparib 6Doxorubicin 6niraparib 5Therapeutics 5Dexamethasone 5pertuzumab 4pazopanib 4lenvatinib 4fludarabine 4cemiplimab 4atezolizumab 4Trastuzumab 4Surveys and Questionnaires 4Psychiatric Rehabilitation 4Polymerase Chain Reaction 4Fulvestrant 4Docetaxel 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × Letrozole × Gynecologic × Clear all
NCT05768139 2026-05-22

PIKALO-1

Eli Lilly and Company

Phase 1/2 Recruiting
880 enrolled
BreastGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡